INTRODUCTION: Inherited susceptibility to lung cancer is understudied. Never smokers are an important subgroup of patients enriched for tumors harboring oncogene aberrations in the EGFR and ALK genes. We aimed to better characterize the incidence of family history of lung cancer among never smokers with NSCLC. METHODS: Clinicopathologic data, tumor genotype, family history of cancer, and specifically family history of lung cancer from 230 consecutive never smokers was retrospectively compiled and analyzed. RESULTS: In our cohort, the median age was 56 years, 67% were women, 75% were white, 59% had advanced NSCLC and 87% had adenocarcinoma histology. In these tumors, 98/230 (42%) had an EGFR mutation, 17/155 (11%) had KRAS mutations and 27/127 (21%) had an ALK translocation. Family history of any cancer was common (57%) and specific family history of lung cancer was present in 42/230 cases (18%). The percentage of cases with family history of lung cancer was higher in the EGFR mutated versus EGFR wild-type NSCLCs. Out of the cases with a family history of any cancer, 22/53 (41.5%) EGFR mutated, 1/5 (20%) KRAS mutated and 3/19 (15.5%) ALK translocated cohorts had a family history of lung cancer. The ratio of family history of lung cancer to family history of cancer was significantly higher in the EGFR mutated cohort when compared to the ALK translocated plus KRAS mutated cohorts (p=0.039). CONCLUSIONS: Family history of lung cancer is common in never smokers with NSCLC, and there seems to be a particular link in families in which the proband has an EGFR mutated tumor when compared to ALK translocated or KRAS mutated tumors. Further study of families with EGFR-mutated NSCLC may yield insights into the pathogenesis of this tumor type.
INTRODUCTION: Inherited susceptibility to lung cancer is understudied. Never smokers are an important subgroup of patients enriched for tumors harboring oncogene aberrations in the EGFR and ALK genes. We aimed to better characterize the incidence of family history of lung cancer among never smokers with NSCLC. METHODS: Clinicopathologic data, tumor genotype, family history of cancer, and specifically family history of lung cancer from 230 consecutive never smokers was retrospectively compiled and analyzed. RESULTS: In our cohort, the median age was 56 years, 67% were women, 75% were white, 59% had advanced NSCLC and 87% had adenocarcinoma histology. In these tumors, 98/230 (42%) had an EGFR mutation, 17/155 (11%) had KRAS mutations and 27/127 (21%) had an ALK translocation. Family history of any cancer was common (57%) and specific family history of lung cancer was present in 42/230 cases (18%). The percentage of cases with family history of lung cancer was higher in the EGFR mutated versus EGFR wild-type NSCLCs. Out of the cases with a family history of any cancer, 22/53 (41.5%) EGFR mutated, 1/5 (20%) KRAS mutated and 3/19 (15.5%) ALK translocated cohorts had a family history of lung cancer. The ratio of family history of lung cancer to family history of cancer was significantly higher in the EGFR mutated cohort when compared to the ALK translocated plus KRAS mutated cohorts (p=0.039). CONCLUSIONS: Family history of lung cancer is common in never smokers with NSCLC, and there seems to be a particular link in families in which the proband has an EGFR mutated tumor when compared to ALK translocated or KRAS mutated tumors. Further study of families with EGFR-mutated NSCLC may yield insights into the pathogenesis of this tumor type.
Authors: Daphne W Bell; Ira Gore; Ross A Okimoto; Nadia Godin-Heymann; Raffaella Sordella; Roseann Mulloy; Sreenath V Sharma; Brian W Brannigan; Gayatry Mohapatra; Jeff Settleman; Daniel A Haber Journal: Nat Genet Date: 2005-10-30 Impact factor: 38.330
Authors: Jolanta Lissowska; Lenka Foretova; Joanna Dabek; David Zaridze; Neonila Szeszenia-Dabrowska; Peter Rudnai; Eleonora Fabianova; Adrian Cassidy; Dana Mates; Vladimir Bencko; Vladimir Janout; Rayjean J Hung; Paul Brennan; Paolo Boffetta Journal: Cancer Causes Control Date: 2010-03-21 Impact factor: 2.506
Authors: Nicolas Girard; Emil Lou; Christopher G Azzoli; Rekha Reddy; Mark Robson; Megan Harlan; Irene Orlow; Yasushi Yatabe; Khedoudja Nafa; Marc Ladanyi; Agnes Viale; Mark G Kris; Gregory Riely; Vincent Miller; Robert J Klein; Keitaro Matsuo; William Pao Journal: Clin Cancer Res Date: 2010-01-12 Impact factor: 12.531
Authors: Haris Vikis; Mitsuo Sato; Michael James; Daolong Wang; Yian Wang; Min Wang; Dongmei Jia; Yan Liu; Joan E Bailey-Wilson; Christopher I Amos; Susan M Pinney; Gloria M Petersen; Mariza de Andrade; Ping Yang; Jonathan S Wiest; Pamela R Fain; Ann G Schwartz; Adi Gazdar; Colette Gaba; Henry Rothschild; Diptasri Mandal; Elena Kupert; Daniela Seminara; Avinash Viswanathan; Ramaswamy Govindan; John Minna; Marshall W Anderson; Ming You Journal: Cancer Res Date: 2007-05-15 Impact factor: 12.701
Authors: Kari G Rabe; Maria A Stevens; Amanda Toledo Hernández; Shruti Chandra; Joleen M Hubbard; Jennifer L Kemppainen; Shounak Majumder; Gloria M Petersen Journal: Genet Med Date: 2022-02-25 Impact factor: 8.864
Authors: Chunxiang Li; Yalong Wang; Kai Su; Yu Liu; Liyu Wang; Bo Zheng; Na Yan; Dawei Yuan; Yanxiang Zhang; Liyan Xue; Shugeng Gao; Jie He Journal: Transl Lung Cancer Res Date: 2021-04